Strata Critical Medical, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
SRTA$6.05+8.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows F-
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows From Operating Activities: | ||
| Net income / (loss) | $41,347 | $(27,307) |
| Adjustments to reconcile net income ( loss) to net cash and restricted cash used in operating activities: | ||
| Gain on sale of business | (56,996) | — |
| Depreciation and amortization | 8,185 | 5,962 |
| Stock-based compensation | 17,832 | 19,893 |
| Change in fair value of warrant liabilities | (4,278) | 850 |
| Change in fair value of other assets and liabilities | 1,037 | — |
| Excess of lease liability over operating right-of-use assets | — | (123) |
| Transaction costs paid related to sale of business | (7,381) | — |
| Gain on lease modification | — | (622) |
| Acquisition consideration allocated to seller transaction expenses | (44,339) | — |
| Impairment of intangible assets | — | 5,759 |
| Impairment of property and equipment | 1,673 | — |
| Realized loss from sale of short-term investments | 5,195 | — |
| Realized foreign exchange gain | (798) | — |
| Accretion of interest income on held-to-maturity securities | (2,214) | (3,990) |
| Deferred tax expense (benefit) | 432 | (255) |
| Other | 471 | 323 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,686) | 6,352 |
| Accounts receivable | (12,034) | (998) |
| Other non-current assets | 666 | (70) |
| Operating right-of-use assets/lease liabilities | (88) | 164 |
| Accounts payable and accrued expenses | 2,378 | (8,338) |
| Deferred revenue | 1,684 | (119) |
| Net cash used in operating activities (includes discontinued operations; see Note 5) | (48,914) | (2,519) |
| Cash Flows From Investing Activities: | ||
| Acquisitions, net of cash acquired | (66,535) | (2,230) |
| Cash transfer from sale of business | (2,810) | — |
| Capitalized software development costs | (1,415) | (2,119) |
| Purchase of property and equipment, net of proceeds from disposal | (9,595) | (30,862) |
| Purchase of held-to-maturity investments | (146,258) | (143,255) |
| Proceeds from maturities of held-to-maturity investments | 226,200 | 177,450 |
| Proceeds from sale of short-term investments | 70,163 | — |
| Net cash provided by / (used in) investing activities (includes discontinued operations; see Note 5) | 69,750 | (1,016) |
| Cash Flows From Financing Activities: | ||
| Proceeds from the exercise of common stock options | 193 | 168 |
| Taxes paid related to net share settlement of equity awards | (9,105) | (5,683) |
| Repurchase and retirement of common stock | — | (244) |
| Net cash used in financing activities (includes discontinued operations; see Note 5) | (8,912) | (5,759) |
| Effect of foreign exchange rate changes on cash balances | (339) | (80) |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 11,585 | (9,374) |
| Cash and cash equivalents and restricted cash - beginning | 19,647 | 29,021 |
| Cash and cash equivalents and restricted cash - ending | $31,232 | $19,647 |
| Reconciliation to consolidated balance sheets (includes discontinued operations; see Note 5) | ||
| Cash and cash equivalents | $30,968 | $18,378 |
| Restricted cash | 264 | 1,269 |
| Total cash and cash equivalents and restricted cash | $31,232 | $19,647 |
| Supplemental cash flow information | ||
| Cash paid for: | ||
| Income Taxes paid | $87 | $— |
| Non-cash investing and financing activities: | ||
| Common stock received for sale of business | $75,357 | $— |
| Contingent consideration and indemnity holdback receivable from sale of business in prepaids and other current assets and other non-current assets, respectively | 36,400 | — |
|---|---|---|
| New leases under ASC 842 entered into during the period | 1,597 | 8,406 |
| Contingent consideration in accounts payable and accrued expenses and other non-current liabilities | 9,072 | — |
| Common stock issued for acquisition | 8,414 | — |
| Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | 128 | 375 |
| Modification of existing right-of-use assets ("ROU") and lease liability | — | 12,684 |
| Derecognition of ROU assets and lease liability | — | (6,367) |
| Common stock issued for settlement of earn-out previously in accounts payable and accrued expenses | — | 3,022 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.